1. Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostate cancer;Murray;J Clin Endocrinol Metab,2001
2. Metabolic bone disease induced by prostate cancer. Rationale for the use of bisphosphonates;Berruti;J Urol,2001
3. Pamidronate administration to bone metastatic prostate cancer patients improves bone metabolic derangement and bone pain;Berruti
4. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment;Vinholes;Cancer Treat Rev,1996
5. Pamidronate administration improves the secondary hyperparathyroidism due to “bone hunger syndrome” in a patient with osteoblastic metastases from prostate cancer;Berruti;Prostate,1997